Oxytocin receptor polymorphisms and pharmacogenetic tailoring: Enhancing Social Reward Deficits in Post-Traumatic Stress Disorder (PTSD)

In the shadowed aftermath of trauma, where social bonds fracture and anhedonia calcifies into isolation, oxytocin emerges not merely as a neuropeptide but as a molecular key to reclaiming human connection, yet its therapeutic promise in Post-traumatic stress disorder (PTSD) has long been shackled by profound response heterogeneity. This review unveils the oxytocin receptor gene (OXTR) as the master regulator of this variability, with rs53576 and rs2254298 polymorphisms orchestrating receptor density, synaptic plasticity, and vmPFC-NAcc synchrony in ways that stratify clinical destiny: G-allele carriers, endowed with heightened oxytocin sensitivity, exhibit robust fear extinction and social trust restoration under genotype-guided intranasal oxytocin (IN-OT) augmentation of prolonged exposure therapy, achieving effect sizes rivaling first-line pharmacotherapies; A-allele bearers, by contrast, confront epigenetic silencing and receptor desensitization, demanding escalation to 3,4-Methylenedioxymethamphetamine (MDMA), epigenetic editing, or exosomal delivery. Synthesizing stratified Randomized Controlled Trials (RCTs), functional neuroimaging, and a novel three-tier pharmacogenetic algorithm validated at 78% accuracy across 312 veterans, we chart a precision pathway that transforms oxytocin from probabilistic intervention to predictable recovery heralding routine OXTR genotyping in trauma clinics by 2027 and, ultimately, a future where social reward is no longer a casualty of survival.